TAK TAKEDA PHARMACEUTICAL CO LTD IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1395064 · Reporting currency JPY
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: JPY | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | 4.58T | 4.26T |
| Cost of revenue | 1.58T | 1.43T |
| Gross profit | 3.00T | 2.84T |
| R&D expense | 730.23B | 729.92B |
| Operating income | 342.59B | 214.07B |
| Interest expense | 137.31B | 119.53B |
| Pretax income | 175.08B | 52.79B |
| Income tax | 66.94B | -91.41B |
| Net income | 107.93B | 144.07B |
| EBITDA | 1.10T | 942.08B |
| EPS (basic) | 68.36 | 92.09 |
| EPS (diluted) | 67.23 | 91.16 |
| Weighted avg. shares (diluted) | 1.61B | 1.58B |
| Balance sheet | ||
| Cash & equivalents | 385.11B | 457.80B |
| Receivables | 709.47B | 668.40B |
| Inventory | 1.22T | 1.21T |
| Current assets | 2.52T | 2.56T |
| PP&E, netmay include right-of-use assets (IFRS) | 1.97T | 1.99T |
| Goodwill | 5.32T | 5.41T |
| Intangibles | 3.63T | 4.27T |
| Total assets | 14.25T | 15.11T |
| Current liabilities | 2.51T | 2.31T |
| Short-term debt | 548.94B | 367.25B |
| Long-term debt | 3.97T | 4.48T |
| Total debt | 4.52T | 4.84T |
| Total liabilities | 7.31T | 7.83T |
| Shareholders' equity | 6.94T | 7.27T |
| Net debt | 4.13T | 4.39T |
| Shares outstanding | 1.59B | 1.58B |
| Cash flow statement | ||
| Operating cash flow | 1.06T | 716.34B |
| Capital expenditure | 200.79B | 175.42B |
| Free cash flow | 856.39B | 540.92B |
| Investing cash flow | -367.06B | -463.86B |
| Financing cash flow | -751.42B | -354.42B |
| Depreciation & amortization | 761.40B | 728.00B |
| Dividends paid | 302.50B | 287.19B |
| Share buybacks | 51.86B | 2.33B |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, JPY, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.